Loading
Building a cell-therapy factory costs tens of millions, so most good academic ideas never reach patients. Shared public facilities would give them a route to the clinic.
The UK Cell and Gene Therapy Catapult, Canada's CCRM and several US academic GMP facilities show that shared, publicly funded manufacturing can carry academic products through early trials. The proposal is a national network of foundries co-located with cancer centres, each with standardised closed automated platforms, a shared quality system, and transparent booking and pricing, funded to provide first-in-human manufacturing at marginal cost for academic and start-up programmes, with a fast route for successful products into the hospital-made network or industry.
Shares Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy, TIL therapy, Manufacturing cost and time for living and radioactive medicines, CAR-T cell therapy.
Shares Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy, TIL therapy, Manufacturing cost and time for living and radioactive medicines, CAR-T cell therapy.
Shares Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy, Manufacturing cost and time for living and radioactive medicines, CAR-T cell therapy.
Shares Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy, Manufacturing cost and time for living and radioactive medicines, CAR-T cell therapy.
Shares Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy, Manufacturing cost and time for living and radioactive medicines, CAR-T cell therapy.
Shares Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy, Manufacturing cost and time for living and radioactive medicines, CAR-T cell therapy.
Shares Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy, Manufacturing cost and time for living and radioactive medicines, CAR-T cell therapy.
Shares Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy, Manufacturing cost and time for living and radioactive medicines, CAR-T cell therapy.